Borosil Scientific Q1 FY27: steady revenue growth, mix shift shapes margins

Borosil Scientific reported a stable start to FY27, with consolidated net sales of 106.8 crore in Q1 FY27, up 11.2 percent year on year from 96.0 crore. Profitability improved sharply versus a weak base, but the quarter also showed how product mix and accounting effects can swing reported margins.

On a consolidated basis, EBITDA came in at 8.7 crore versus 5.8 crore a year ago, a 50.1 percent increase. EBIT rose to 3.8 crore from 0.9 crore. Profit after tax (PAT) turned positive at 4.4 crore compared with a loss of 4.2 crore in Q1 FY26.

Standalone numbers tracked a similar direction. Standalone net sales were 99.9 crore, up 12.2 percent year on year, with EBITDA at 11.5 crore and PAT at 6.8 crore. The company also ended the quarter with net cash. Net debt was negative 136.8 crore on a consolidated basis and negative 143.3 crore on a standalone basis.

This quarter sits in a broader story. Since the scientific division was demerged from Borosil Ltd in December 2023 and listed as Borosil Scientific Limited in June 2024, the company has been positioning itself not just as a laboratory glassware leader but as a broader lab and process solutions provider spanning lab consumables, lab equipment, process systems, pharma primary packaging, and domestic glassware.

Where growth came from in Q1 FY27

The topline growth was driven by strong momentum in the glassware segment, while the core lab consumables business was flat in reported terms.

In the scientific segment, consolidated lab consumables revenue was 45.8 crore, effectively unchanged from 45.9 crore in Q1 FY26. Lab equipment, sold under the LabQuest brand, grew 31.4 percent year on year to 12.3 crore from 9.4 crore. Process systems revenue increased 8.6 percent to 8.5 crore.

The glassware segment provided the sharper uplift. Pharma primary packaging revenue increased 31.6 percent to 23.1 crore from 17.5 crore. Domestic glassware grew 4.0 percent to 15.3 crore from 14.7 crore.

The company also flagged an important qualifier: lab consumables revenue in the period was impacted by Ind AS 115. Excluding this impact, revenue growth in lab consumables and across all product categories was 7.4 percent and 14.6 percent, respectively. That detail matters because it suggests underlying demand may be healthier than the reported flat figure indicates, even if the reported P and L does not fully show it.

Behind the segment numbers is a clear strategic intent. Borosil Scientific has been using its long standing brand equity in laboratory glassware to diversify into adjacent verticals that expand wallet share within the same customer base. The portfolio now spans BOROSIL lab glassware and consumables, LabQuest instruments, Borosil Process Sciences systems, and Borosil Klasspack pharma packaging.

Financial summary

Notes: Operating EBITDA and EBIT exclude investment income of 2.41 crore in Q1 FY27, 1.73 crore in Q4 FY26, and 1.99 crore in Q1 FY26. Q1 FY26 PAT was impacted by exceptional items of 6.61 crore related to a voluntary retirement scheme at the Nashik plant.

Mix, margins, and what the quarter signals

A key takeaway from Q1 FY27 is that Borosil Scientific is still in the middle of a mix transition. The company’s medium term goals explicitly call out margin improvement through higher focus on process sciences and lab equipment due to their higher profit margins, alongside continued margin work in lab glassware and consumables.

The Q1 segment mix already hints at that direction. Lab equipment and process systems together contributed 20.8 crore in Q1 FY27, up from 17.3 crore in Q1 FY26. But the biggest year on year step up came from pharma primary packaging, which is part of the glassware segment and grew to 23.1 crore. That matters because the margin profile can differ meaningfully by category. Investors should watch whether growth continues to broaden across LabQuest and Process Sciences, since management has positioned those as key levers for sustained EBITDA improvement.

Another signal sits in the consolidated margin spread versus standalone. Consolidated EBITDA margin was 8.2 percent in Q1 FY27, well below the standalone margin of 11.5 percent. It is also far below the unusually high consolidated margin in Q4 FY26. The presentation does not provide a detailed bridge, but the divergence reinforces that this is a portfolio company. Consolidated profitability will depend on how fast higher margin categories scale and how consistently the broader group manages operating costs.

The company’s customer mix shows it is not dependent on a single end market. Within the scientific segment, key pharma and other pharma together form a large share, but there is also meaningful presence across chemical and allied industries, food and feed, cement and steel, and research. The presentation also points to demand tailwinds such as growing food and beverage testing and the Union Budget 2026 to 27 launch of Biopharma SHAKTI, which could expand biologics and biosimilars activity and, by extension, lab requirements.

Strategy in execution: Make in India, exports, and product development

Borosil Scientific’s narrative is anchored around domestic capability and breadth. It operates across four manufacturing locations in India and maintains four warehouses with over 150 channel partners. The portfolio spans more than 4,500 SKUs and reaches over 90 export countries.

The company positions itself as a beneficiary of the Make in India push and the global shift toward localized manufacturing under the China Plus One approach. It also notes that a reversal in US tariffs should support the high margin export business, and that planned capital expenditure to expand volumes puts it in a stronger position for the next phase of growth.

Importantly, Borosil Scientific is not presenting Make in India as a slogan. The presentation highlights in house calibration labs, automation systems, and IoT enabled production monitoring, alongside R and D integration. It points to innovations such as a patented bottle top dispenser with DIY calibration and QR coded volumetric glassware.

Product development remains a visible lever. The company listed new products under development or launch themes including moisture analyser, handheld photometer, UV visible spectrophotometer, e dispenser, e titrate, overhead stirrer, hot plate stirrer, quartz distillation unit, vial inserts, micro vials, and testing solutions such as fat and fiber related offerings. It also highlighted a lab water collaboration under the stakpure line, positioned as a value choice for laboratory water and described as combining Borosil Scientific’s reach and service with partner technology.

For investors, the key question is not how long the list is, but whether these additions translate into repeatable sales through the company’s distribution and service network. The company’s emphasis on service, application labs, prototyping infrastructure, and a service centre suggests it is building the backbone needed to make instruments and systems businesses durable.

Segment sales comparison

Market runway and what management is targeting

Borosil Scientific’s opportunity set is larger than its legacy category. In India, it estimates the serviceable addressable market at around 600 crore for laboratory glassware and consumables, 755 crore for laboratory equipment, 1,242 crore for process equipment, and 1,377 crore for pharma primary packaging. The growth rates it cites range from 6 to 8 percent for lab consumables and lab equipment to 12 to 14 percent for process equipment and 9 to 10 percent for pharma primary packaging.

The company’s medium term goals are straightforward. It is targeting a revenue CAGR of 12 to 14 percent, supported by sustained leadership in pharmaceutical laboratory glassware, higher exports, and expansion of LabQuest and Process Sciences within existing accounts. On margins, management has highlighted four levers: mix shift toward process sciences and lab equipment, improvement in glassware and consumables margins, annual pricing actions, and tight expense control, alongside a push toward renewable energy.

The ESG section suggests some of that energy work is already in progress. The company commissioned a 450 kW solar rooftop project in February 2025, installed three rain water harvesting systems, and commissioned a 10 KLD sewage treatment plant for recycling wastewater in October 2024. While ESG disclosures do not directly translate to quarterly earnings, they can support cost stability and compliance readiness, especially in audited pharma and export supply chains.

Closing view: a portfolio business leaning into breadth

Q1 FY27 did not deliver one single story. It delivered several smaller ones that together describe where Borosil Scientific is headed.

First, growth is broadening. Pharma packaging and lab equipment posted strong year on year growth, and process systems continued to expand. Second, the core lab consumables line looked flat in reported numbers, but the company has clearly attributed a portion of that to Ind AS 115, implying better underlying momentum. Third, margins are still sensitive to mix and consolidation dynamics, which is expected for a company building scale across instruments, systems, and packaging.

The strategic theme remains consistent with what the company has communicated since the demerger and listing. Borosil Scientific is using its brand in laboratory glassware as a base, then layering on higher value categories like lab equipment and process systems, while keeping pharma primary packaging as a meaningful growth engine. If execution continues and the mix shifts as intended, the medium term goal of 12 to 14 percent revenue CAGR and improving EBITDA margins becomes easier to underwrite.

For investors, the practical takeaway is to track three indicators over the next few quarters: reported versus underlying growth in lab consumables given the Ind AS 115 impact, the scaling trajectory of LabQuest and Process Sciences, and the consistency of consolidated margins as the portfolio expands. The quarter shows the building blocks are in place. The next test is whether the company can convert its breadth into steadier profitability.